IP Library Granted Patent US 8,668,906
Granted Patent B2
US 8,668,906 · App. 13/500,799 · Granted Mar 11, 2014

Patent

Inventor: Jordi Cuñé Castellana (Bellaterra, ES)
Assignee: Ab-Biotics S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,668,906
App. No.
13/500,799
Granted
Mar 11, 2014
Kind
B2
Abstract

The invention relates to a composition comprising an effective amount of at least one of the strains selected from the group consisting of Lactobacillus plantarum CECT 7527, Lactobacillus plantarum CECT 7528, and Lactobacillus plantarum CECT 7529, These new strains have good probiotic features and are useful for the prevention and/or the treatment of cardiovascular disorders.

Claims (18)

1. A composition comprising an effective amount of at least one of the strains selected from the group consisting of Lactobacillus plantarum CECT 7527 , Lactobacillus plantarum CECT 7528 , Lactobacillus plantarum CECT 7529, and mutant strains thereof, wherein the mutant strains are obtained by using the deposited strains as starter material, and wherein the mutant strains retain or further improve the cholesterol lowering activity of the parent strains.

2. The composition according to claim 1 , which comprises an effective amount of the strains Lactobacillus plantarum CECT 7527 , Lactobacillus plantarum CECT 7528, and Lactobacillus plantarum CECT 7529.

3. A pharmaceutical and/or veterinary product comprising an effective amount of the composition of claim 1 , together with appropriate amounts of pharmaceutically or veterinary acceptable excipients.

4. An edible product comprising an effective amount of the composition of claim 1 , together with appropriate amounts of other edible ingredients.

5. The edible product according to claim 4 , which is a dietary supplement.

6. The edible product according to claim 5 , which is a nutraceutical.

7. The edible product according to claim 4 , which is in the form of a tablet, capsule, syrup or pill.

8. The edible product according to claim 4 , which is a dairy product or a meat product.

9. A strain of Lactobacillus plantarum selected from the group consisting of Lactobacillus plantarum CECT 7527 , Lactobacillus plantarum CECT 7528 and Lactobacillus plantarum CECT 7529.

10. The composition according to claim 1 , which comprises an effective amount of at least one of the strains selected from the group consisting of Lactobacillus plantarum CECT 7527 , Lactobacillus plantarum CECT 7528, and Lactobacillus plantarum CECT 7529.

11. A method for the prevention and/or treatment of cardiovascular disorders in an animal, including a human, comprising:

administering to said animal in need thereof the composition of claim 1 .

12. The method according to claim 11 , which comprises administering an effective amount of the composition in combination with statins.

13. The method according to claim 11 , wherein the animal, including human, is sterol hyperabsorbent.

14. A method for reducing cholesterol in an animal, including a human, comprising:

administering to said animal in need thereof the composition of claim 1 .

15. The method according to claim 14 , which comprises administering an effective amount of the composition in combination with statins.

16. The method according to claim 14 , wherein the animal, including human, is sterol hyperabsorbent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2012
From: CUNE CASTELLANA, JORDI
To: AB-BIOTICS S.A.
Reel/Frame 028043/0001 →
Priority Claims (1)
EP 09172613 · Oct 9, 2009 · regional
Continuity (2)
Provisional Application 61265095 · Nov 30, 2009
Related Publication 20120213753A1 · Aug 23, 2012